Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ascendis Pharma (Nasdaq: ASND) will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. ET in San Francisco.
A live webcast will be available via the Investors & News section of Ascendis Pharma's website at investors.ascendispharma.com, and a replay will be posted on the site shortly after the presentation and remain available for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ASND
On the day this news was published, ASND declined 0.07%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves were mixed: BBIO up 2.21%, EXEL up 0.14%, while IONS and SMMT declined 0.26% and 1.3%, suggesting stock-specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Regulatory timeline update | Negative | -1.1% | FDA classified new data as major amendment, extending PDUFA to Feb 28, 2026. |
| Nov 17 | Clinical trial results | Positive | +0.3% | Pivotal ApproaCH trial showed higher growth velocity and favorable safety in achondroplasia. |
| Nov 12 | Quarterly earnings | Neutral | -1.0% | Q3 2025 revenue growth and operating profit offset by net loss from finance expense. |
| Nov 07 | Clinical data update | Positive | -0.8% | Three-year pooled analysis showed sustained renal improvements in TransCon PTH–treated adults. |
| Nov 05 | Earnings conference notice | Neutral | +0.8% | Announcement of Q3 2025 results date and investor webcast details. |
Recent news spanning clinical data, regulatory updates, and earnings has produced only modest single-day price moves, with both aligned and divergent reactions to generally positive developments.
Over the last few months, Ascendis reported multiple milestones. A 3-year pooled analysis for TransCon PTH and pivotal ApproaCH trial results for TransCon CNP highlighted sustained clinical benefits. Q3 2025 results showed revenue rising to €213.6M with continued net losses and notable finance expenses. The FDA later extended the TransCon CNP PDUFA date to Feb 28, 2026. Today’s J.P. Morgan conference participation notice fits into this pattern of regular clinical, regulatory, and investor communications.
Market Pulse Summary
This announcement outlines Ascendis’ plan to present a business update at the J.P. Morgan Healthcare Conference on January 12, 2026. It follows recent clinical, regulatory, and financial disclosures, including pivotal TransCon CNP data and Q3 2025 results. The event may provide additional color rather than entirely new catalysts. Investors may watch for commentary on regulatory timelines, commercial performance, and pipeline priorities during the webcast and subsequent 30-day replay period.
Key Terms
webcast technical
AI-generated analysis. Not financial advice.
COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a business update on Monday, January 12, 2026, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time in San Francisco, California.
A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (ii) Ascendis’ ability to apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © January 2026 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Chad Fugere | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | media@ascendispharma.com |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com |
FAQ
When will Ascendis Pharma (ASND) present at the J.P. Morgan Healthcare Conference in 2026?
How can investors watch Ascendis Pharma's (ASND) January 12, 2026 presentation?
Will there be a replay of Ascendis Pharma's (ASND) J.P. Morgan presentation and for how long?
What time is Ascendis Pharma's (ASND) presentation in Pacific Time on January 12, 2026?
Where in San Francisco will Ascendis Pharma (ASND) present at the 44th Annual J.P. Morgan Healthcare Conference?
